LE WE PMID CA
Arthritis (rheumatoid)232Arthritis (rheumatoide)

Abatacept ttCTLA4Conjugate

Anakinra

Angiogenesis

Arthritis (rheumatoid)

Autoantibodies Anti CCP

Autoantibodies Rheuma factor

Bacillus calmette guerin

Bartonella henselae

Bone (Imaging)

Bone (MRT)

c Jun

Calcium (Hypercalciemia)

Calreticulin

Candida (BASKET)

Certolizumab ttTNFalpha

Cholinergergic antiinflammatory pathway

Clinical Examination (Musculoskeletal system)

Coccidioidomycosis

Crohn s disease

Cryptococcosis

Dendritic cell (Immunology)

Endothelium

Estrogen

Fat necrosis subcutaneous of the newborn

Fibroblast like synoviocytes

Fibroblast

Foot and ankle (Diseases)

Fractalkine

Gastrointestinal stromal cell tumor GIST

Glutamate (Mediator non neuronal)

Hand and wrist (Traumatology)

Histone deacetylase

Histoplasmosis

Infliximab ttTNFalpha

Interleukin17

Interleukin18

Interleukin24 MDA7

Interleukin6

Interleukin7

Langerhans cell histiocytosis

Lepra

Liver (Diseases)

Lung (Diseases interstitial)

Lung (Lipoid pneumonia)

Lung (Toxicology)

Lung and bronchial system (Neoplasia)

Lymphoma (BASKET)

Lymphoma (Hodgkin)

Methotrexate

Mycobacterium avium

Osteoarthritis

Ovary (Neoplasia)

Paracoccoidomycosis

Pharmacogenomics

Pneumocystis carinii Pneumocystis jirovicii

Polymyositis

Proteus spp

Pseudolymphoma (Lymphomatoid granulomatosis)

Pseudolymphoma (Plasma cell granuloma)

Psoriasis

Receptor (Acetylcholine nicotinic)

Regulatory T cell

Rituximab ttCD20

RNA (MicroRNA)

Sarcoidosis

SE (rheumatoid arthritis shared epitope)

Silicone

Slack skin disease

STAT6

Systemic lupus erythematosus

T cell (Th17)

T cell (Th2)

Testis (Neoplasia Seminoma)

Testis (Neoplasia)

TNF alpha antagonist

Tocilizumab ttIL6

Toll like receptor

Tuberculosis

Ustekinumab ttIL12 ttIL23

Wegener s granulomatosis

2006  
1
Treatment of rheumatoid arthritis.
[16424492] BMJ 332(7534): 152-5 (2006)
1995  
2
ABC of rheumatology. Rheumatoid arthritis--II: Treatment.
[7703756] BMJ 310(6980): 652-5 (1995)
1995  
3
ABC of rheumatology. Rheumatoid arthritis--I: Clinical features and diagnosis.
[7888939] BMJ 310(6979): 587-90 (1995)
1993  
4
Medical management of rheumatoid arthritis.
[8374456] BMJ 307(6901): 425-8 (1993)
1979  
5
Fifty years of gold in rheumatoid arthritis.
[421084] Br Med J 1(6159): 289-90 (1979)
2010  
6
Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis.
[20195397] Korean J Intern Med 25(1): 1-17 (2010)
1993  
7
Approach to initial medical treatment of rheumatoid arthritis.
[8118571] Arch Fam Med 2(5): 545-51 (1993)
2004  
8
Diagnosis of early rheumatoid arthritis: what the non-specialist needs to know.
[15340020] J R Soc Med 97(9): 421-4 (2004)
1996  
9
Managing early presentation of rheumatoid arthritis. Systematic overview.
[8688694] Can Fam Physician 42(): 913-22 (1996)
2008  
10
Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs.
[18537958] Br J Clin Pharmacol 66(2): 173-8 (2008)
2008  
11
Review of tocilizumab in the treatment of rheumatoid arthritis.
[19707430] Biologics 2(1): 75-82 (2008)
2007  
12
Targeted therapies in rheumatoid arthritis: Focus on rituximab.
[19707303] Biologics 1(4): 325-33 (2007)
2010  
13
Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis.
[20635831] J Manag Care Pharm 16(6): 402-16 (2010)
2006  
14
Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis.
[16981801] J Manag Care Pharm 12(7): 555-69 (2006)
2010  
15
Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis.
[20421913] Ther Clin Risk Manag 6(): 143-52 (2010)
2007  
16
A systematic review of infliximab in the treatment of early rheumatoid arthritis.
[18473014] Ther Clin Risk Manag 3(5): 905-11 (2007)
2006  
17
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
[17049139] Health Technol Assess 10(42): iii-iv, xi-xiii, 1-229 (2006)
2004  
18
The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
[15130461] Health Technol Assess 8(18): iii-iv, ix-x, 1-105 (2004)
2006  
19
Rheumatoid arthritis is an autoimmune disease triggered by Proteus urinary tract infection.
[16603443] Clin Dev Immunol 13(1): 41-8 (2006)
1999  
20
Dendritic cells and the pathogenesis of rheumatoid arthritis.
[10449169] J Leukoc Biol 66(2): 286-92 (1999)
2009  
21
A systematic review and meta-analysis of the efficacy and safety of etanercept for treating rheumatoid arthritis.
[19751268] Scand J Immunol 70(4): 337-44 (2009)
2005  
22
New therapies for rheumatoid arthritis.
[15807842] Clin Exp Immunol 140(2): 195-204 (2005)
2007  
23
Angiogenesis as a therapeutic target in arthritis: learning the lessons of the colorectal cancer experience.
[17805984] Angiogenesis 10(4): 243-58 (2007)
1998  
24
Angiogenesis in arthritis: role in disease pathogenesis and as a potential therapeutic target.
[14517450] Angiogenesis 2(4): 295-307 (1998)
2009  
25
Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research.
[19060002] Ann Rheum Dis 68(7): 1100-4 (2009)
2009  
26
Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis.
[19054823] Ann Rheum Dis 68(7): 1105-12 (2009)
2009  
27
Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative.
[19033291] Ann Rheum Dis 68(7): 1086-93 (2009)
2009  
28
Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature.
[19033290] Ann Rheum Dis 68(7): 1094-9 (2009)
2008  
29
The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis.
[17827184] Ann Rheum Dis 67(7): 909-16 (2008)
2006  
30
Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors.
[16644783] Ann Rheum Dis 65(10): 1373-8 (2006)
2006  
31
Clinical practice decision tree for the choice of the first disease modifying antirheumatic drug for very early rheumatoid arthritis: a 2004 proposal of the French Society of Rheumatology.
[15994280] Ann Rheum Dis 65(1): 45-50 (2006)
2004  
32
What precedes development of rheumatoid arthritis?
[15479868] Ann Rheum Dis 63 Suppl 2(): ii28-ii31 (2004)
2004  
33
Appropriate and effective management of rheumatoid arthritis.
[15140767] Ann Rheum Dis 63(6): 627-33 (2004)
2003  
34
Angiogenesis as a target in rheumatoid arthritis.
[14532152] Ann Rheum Dis 62 Suppl 2(): ii60-7 (2003)
2001  
35
"Stepping-up" from methotrexate: a systematic review of randomised placebo controlled trials in patients with rheumatoid arthritis with an incomplete response to methotrexate.
[11890654] Ann Rheum Dis 60 Suppl 3(-): iii51-4 (2001)
2000  
36
The final pathogenetic steps in focal bone erosions in rheumatoid arthritis.
[11053093] Ann Rheum Dis 59 Suppl 1(-): i72-4 (2000)
2000  
37
The role of angiogenesis in rheumatoid arthritis: recent developments.
[11053092] Ann Rheum Dis 59 Suppl 1(-): i65-71 (2000)
1999  
38
Rheumatoid arthritis: a synovial disease?
[10577956] Ann Rheum Dis 58(12): 727-30 (1999)
1993  
39
Second line (disease modifying) treatment in rheumatoid arthritis: which drug for which patient?
[8100702] Ann Rheum Dis 52(6): 423-8 (1993)
1993  
40
Molecular and cellular mechanisms of joint destruction in rheumatoid arthritis: two cellular mechanisms explain joint destruction?
[8481058] Ann Rheum Dis 52 Suppl 1(-): S39-47 (1993)
1993  
41
A reappraisal of the evidence that rheumatoid arthritis and several other idiopathic diseases are slow bacterial infections.
[8481057] Ann Rheum Dis 52 Suppl 1(-): S30-8 (1993)
1992  
42
Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications.
[1378718] Ann Rheum Dis 51(7): 919-25 (1992)
1992  
43
Local immune responses in certain extra-articular manifestations of rheumatoid arthritis.
[1616345] Ann Rheum Dis 51(5): 698-701 (1992)
1988  
44
Synovial lining cell hyperplasia in rheumatoid arthritis: dogma and fact.
[3284489] Ann Rheum Dis 47(4): 348-9 (1988)
1982  
45
Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)). Clinical side-effects and laboratory abnormalities.
[7065742] Ann Rheum Dis 41 Suppl 1(-): 44-7 (1982)
1981  
46
Heberden Oration 1980: aspects of the cell biology of the rheumatoid synovial lesion.
[6272658] Ann Rheum Dis 40(5): 433-48 (1981)
1970  
47
Heberden Oration, 1969. Rheumatoid arthritis--nature or nurture?
[4916766] Ann Rheum Dis 29(4): 357-79 (1970)
1962  
48
Femoral Head Destruction in Rheumatoid Arthritis and Osteo-Arthritis: A Clinical Review of 27 Cases.
[18623865] Ann Rheum Dis 21(1): 23-30 (1962)
1960  
49
The Experimental Production of Arthritis: A Review.
[18623856] Ann Rheum Dis 19(4): 297-317 (1960)
2009  
50
Developments in the scientific understanding of rheumatoid arthritis.
[19835638] Arthritis Res Ther 11(5): 249 (2009)
2008  
51
Abatacept in the treatment of rheumatoid arthritis.
[19007425] Arthritis Res Ther 10 Suppl 1(): S5 (2008)
2008  
52
High avidity autoreactive T cells with a low signalling capacity through the T-cell receptor: central to rheumatoid arthritis pathogenesis?
[18710589] Arthritis Res Ther 10(4): 210 (2008)
2007  
53
Cells of the synovium in rheumatoid arthritis. Chondrocytes.
[18001488] Arthritis Res Ther 9(5): 220 (2007)
2007  
54
Vasculopathy and disordered angiogenesis in selected rheumatic diseases: rheumatoid arthritis and systemic sclerosis.
[17767741] Arthritis Res Ther 9 Suppl 2(): S3 (2007)
2007  
55
Cells of the synovium in rheumatoid arthritis. B cells.
[17349064] Arthritis Res Ther 9(2): 205 (2007)
2007  
56
Cells of the synovium in rheumatoid arthritis. Osteoclasts.
[17316459] Arthritis Res Ther 9(1): 203 (2007)
2007  
57
Cells of the synovium in rheumatoid arthritis. T lymphocytes.
[17306038] Arthritis Res Ther 9(1): 202 (2007)
2007  
58
Mesenchymal stromal cells. Nurse-like cells reside in the synovial tissue and bone marrow in rheumatoid arthritis.
[17306036] Arthritis Res Ther 9(1): 201 (2007)
2006  
59
What is MRI bone oedema in rheumatoid arthritis and why does it matter?
[17169137] Arthritis Res Ther 8(6): 222 (2006)
2006  
60
Aspects of early arthritis. Definition of disease states in early arthritis: remission versus minimal disease activity.
[16879719] Arthritis Res Ther 8(4): 216 (2006)
2006  
61
Aspects of early arthritis. What determines the evolution of early undifferentiated arthritis and rheumatoid arthritis? An update from the Norfolk Arthritis Register.
[16817941] Arthritis Res Ther 8(4): 214 (2006)
2006  
62
Aspects of early arthritis. Traditional DMARD therapy: is it sufficient?
[16719936] Arthritis Res Ther 8(3): 211 (2006)
2005  
63
Rheumatoid arthritis as a hyper-endoplasmic-reticulum-associated degradation disease.
[16207344] Arthritis Res Ther 7(5): 181-6 (2005)
2005  
64
Regulatory T cells in rheumatoid arthritis.
[15899057] Arthritis Res Ther 7(3): 93 (2005)
2004  
65
Endothelial cell phenotypes in the rheumatoid synovium: activated, angiogenic, apoptotic and leaky.
[15059266] Arthritis Res Ther 6(2): 60-72 (2004)
2003  
66
The value of sensitive imaging modalities in rheumatoid arthritis.
[12932279] Arthritis Res Ther 5(5): 210-3 (2003)
2009  
67
Developments in the clinical understanding of rheumatoid arthritis.
[19232060] Arthritis Res Ther 11(1): 204 (2009)
1999  
68
Rheumatoid arthritis: a review and suggested dental care considerations.
[10332134] J Am Dent Assoc 130(5): 689-98 (1999)
2008  
69
Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis.
[18025440] Ann Intern Med 148(2): 124-34 (2008)
1989  
70
The use of disease modifying antirheumatic drugs in the management of rheumatoid arthritis.
[2694146] Postgrad Med J 65(770): 905-12 (1989)
2002  
71
The molecular mechanism of osteoclastogenesis in rheumatoid arthritis.
[12223101] Arthritis Res 4(5): 281-9 (2002)
2008  
72
Recent developments in the immunobiology of rheumatoid arthritis.
[18373887] Arthritis Res Ther 10(2): 204 (2008)
2003  
73
Understanding the window of opportunity concept in early rheumatoid arthritis.
[12847667] Arthritis Rheum 48(7): 1771-4 (2003)
2000  
74
The pathogenesis and prevention of joint damage in rheumatoid arthritis: advances from synovial biopsy and tissue analysis.
[11145019] Arthritis Rheum 43(12): 2619-33 (2000)
2006  
75
Synovial fibroblasts: key players in rheumatoid arthritis.
[16567358] Rheumatology (Oxford) 45(6): 669-75 (2006)
2003  
76
Pathogenesis of bone and cartilage destruction in rheumatoid arthritis.
[12817090] Rheumatology (Oxford) 42 Suppl 2(): ii11-6 (2003)
2001  
77
The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence?
[11709604] Rheumatology (Oxford) 40(11): 1211-20 (2001)
2000  
78
Radiographic imaging: the 'gold standard' for assessment of disease progression in rheumatoid arthritis.
[11001374] Rheumatology (Oxford) 39 Suppl 1(-): 9-16 (2000)
2007  
79
Early rheumatoid arthritis: a review of MRI and sonographic findings.
[18029892] AJR Am J Roentgenol 189(6): 1502-9 (2007)
2005  
80
Rheumatoid arthritis: a practical guide to state-of-the-art imaging, image interpretation, and clinical implications.
[15798057] Radiographics 25(2): 381-98 (2005)
2010  
81
Tocilizumab - a new step in rheumatoid arthritis treatment.
[20975633] Acta Reumatol Port 35(3): 302-12 (2010)
2008  
82
Dendritic cell subsets: their roles in rheumatoid arthritis.
[18344920] Acta Reumatol Port 33(1): 35-45 (2008)
2008  
83
2010  
84
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.
[20444750] Ann Rheum Dis 69(6): 964-75 (2010)
2011  
85
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.
[21378402] Ann Rheum Dis 70(6): 909-20 (2011)
2003  
86
Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years.
[12860726] Ann Rheum Dis 62(8): 722-7 (2003)
2007  
87
Amplifying elements of arthritis and joint destruction.
[17934095] Ann Rheum Dis 66 Suppl 3(-): iii45-8 (2007)
2007  
88
A vital clue to deciphering bone pathology: MRI bone oedema in rheumatoid arthritis and osteoarthritis.
[17998216] Ann Rheum Dis 66(12): 1549-52 (2007)
2007  
89
QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries.
[17412740] Ann Rheum Dis 66(11): 1491-6 (2007)
2007  
90
The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice.
[17426065] Ann Rheum Dis 66(11): 1473-8 (2007)
2007  
91
Cellular targets of interleukin-18 in rheumatoid arthritis.
[17502360] Ann Rheum Dis 66(11): 1411-8 (2007)
2007  
92
Actin cytoskeleton dynamics linked to synovial fibroblast activation as a novel pathogenic principle in TNF-driven arthritis.
[17934089] Ann Rheum Dis 66 Suppl 3(-): iii23-8 (2007)
2005  
93
X linked agammaglobulinaemia and rheumatoid arthritis.
[15564308] Ann Rheum Dis 64(7): 1075-8 (2005)
2002  
94
Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value.
[11879544] Arthritis Res 4(2): 87-93 (2002)
2003  
95
Roles of B cells in rheumatoid arthritis.
[15180890] Arthritis Res Ther 5 Suppl 4(-): S1-6 (2003)
2003  
96
Targeting B cells for the treatment of rheumatoid arthritis.
[15180891] Arthritis Res Ther 5 Suppl 4(-): S7-11 (2003)
2010  
97
Central role of nitric oxide in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus.
[20609263] Arthritis Res Ther 12(3): 210 (2010)
2010  
98
The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis.
[20236483] Arthritis Res Ther 12(1): 203 (2010)
2010  
99
Vasculogenesis in rheumatoid arthritis.
[20346090] Arthritis Res Ther 12(2): 110 (2010)
2007  
100
Cells of the synovium in rheumatoid arthritis. Dendritic cells.
[17850683] Arthritis Res Ther 9(4): 219 (2007)
2009  
101
Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review.
[19368701] Arthritis Res Ther 11 Suppl 1(-): S1 (2009)
2009  
102
Hypoxia. The role of hypoxia and HIF-dependent signalling events in rheumatoid arthritis.
[19222864] Arthritis Res Ther 11(1): 201 (2009)
2008  
103
Dynamic interactions between T cells and dendritic cells and their derived cytokines/chemokines in the rheumatoid synovium.
[19007422] Arthritis Res Ther 10 Suppl 1(-): S2 (2008)
2008  
104
Advances in the genetics of rheumatoid arthritis point to subclassification into distinct disease subsets.
[18394179] Arthritis Res Ther 10(2): 205 (2008)
2010  
105
The American College of Rheumatology/European League Against Rheumatism criteria for the classification of rheumatoid arthritis: a game changer.
[20872597] Arthritis Rheum 62(9): 2592-4 (2010)
2010  
106
The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report.
[20872596] Arthritis Rheum 62(9): 2582-91 (2010)
2004  
107
The synovium in rheumatoid arthritis: evidence for (at least) two pathologies.
[14730593] Arthritis Rheum 50(1): 1-4 (2004)
2009  
108
Getting them even earlier: Identifying individuals before clinical presentation with rheumatoid arthritis.
[19950327] Arthritis Rheum 61(12): 1620-2 (2009)
2003  
109
Interleukin-17 in rheumatoid arthritis: if T cells were to contribute to inflammation and destruction through synergy.
[12632409] Arthritis Rheum 48(3): 594-601 (2003)
2010  
110
Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons.
[20560138] Arthritis Rheum 62(10): 2852-63 (2010)
2009  
111
Contrast in aberrant microRNA expression in systemic lupus erythematosus and rheumatoid arthritis: is microRNA-146 all we need?
[19333929] Arthritis Rheum 60(4): 912-5 (2009)
2009  
112
Defining remission in rheumatoid arthritis: results of an initial American College of Rheumatology/European League Against Rheumatism consensus conference.
[19405006] Arthritis Rheum 61(5): 704-10 (2009)
2008  
113
Pathophysiology of rheumatoid arthritis: split or lump?
[18821696] Arthritis Rheum 58(10): 2925-7 (2008)
2008  
114
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.
[18512708] Arthritis Rheum 59(6): 762-84 (2008)
2008  
115
Lymphoid follicles in joints: what do they mean?
[18512771] Arthritis Rheum 58(6): 1563-5 (2008)
2009  
116
Rheumatoid arthritis does not share most of the newly identified systemic lupus erythematosus genetic factors.
[19714582] Arthritis Rheum 60(9): 2558-64 (2009)
2008  
117
1958 revision of diagnostic criteria for rheumatoid arthritis.
[18240261] Arthritis Rheum 58(2 Suppl): S15-9 (2008)
2010  
118
Aggressive treatment of early rheumatoid arthritis: recognizing the window of opportunity and treating to target goals.
[21517638] Am J Manag Care 16(9 Suppl): S249-58 (2010)
2010  
119
Preventing the progression from undifferentiated arthritis to rheumatoid arthritis: the clinical and economic implications.
[21517637] Am J Manag Care 16(9 Suppl): S243-8 (2010)
2003  
120
Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate.
[14577718] Am J Manag Care 9(6 Suppl): S136-43 (2003)
2008  
121
Patients with suspected rheumatoid arthritis should be referred early to rheumatology.
[18219044] BMJ 336(7637): 215-6 (2008)
2006  
122
Advantages and limitations of quantitative measures to assess rheumatoid arthritis: joint counts, radiographs, laboratory tests, and patient questionnaires.
[17121487] Bull NYU Hosp Jt Dis 64(1-2): 32-9 (2006)
2006  
123
The role of the synovial fibroblast in rheumatoid arthritis: cartilage destruction and the regulation of matrix metalloproteinases.
[17121485] Bull NYU Hosp Jt Dis 64(1-2): 20-4 (2006)
2006  
124
The pathogenesis of rheumatoid arthritis.
[17121483] Bull NYU Hosp Jt Dis 64(1-2): 12-5 (2006)
2010  
125
T-cell agents in the treatment of rheumatoid arthritis.
[20969545] Bull NYU Hosp Jt Dis 68(3): 162-5 (2010)
2010  
126
Anti-interleukin-6 therapy in rheumatoid arthritis.
[20969554] Bull NYU Hosp Jt Dis 68(3): 211-7 (2010)
2007  
127
Interleukin-6 in the pathogenesis of rheumatoid arthritis.
[17708744] Bull NYU Hosp Jt Dis 65 Suppl 1(-): S4-10 (2007)
2007  
128
Predicting response to TNF antagonists in rheumatoid arthritis: the promise of pharmacogenetics research using clinical registries.
[17581108] Bull NYU Hosp Jt Dis 65(2): 139-42 (2007)
2007  
129
Interleukin-6--a key mediator of systemic and local symptoms in rheumatoid arthritis.
[17708739] Bull NYU Hosp Jt Dis 65 Suppl 1(-): S11-5 (2007)
2007  
130
Interleukin-6 inhibition and clinical efficacy in rheumatoid arthritis treatment--data from randomized clinical trials.
[17708740] Bull NYU Hosp Jt Dis 65 Suppl 1(-): S16-20 (2007)
2009  
131
Monitoring response to therapy in rheumatoid arthritis - perspectives from the clinic.
[19583560] Bull NYU Hosp Jt Dis 67(2): 236-42 (2009)
2008  
132
Limitations of a quantitative swollen and tender joint count to assess and monitor patients with rheumatoid arthritis.
[18937635] Bull NYU Hosp Jt Dis 66(3): 216-23 (2008)
2008  
133
Emerging therapeutics for rheumatoid arthritis.
[18937634] Bull NYU Hosp Jt Dis 66(3): 210-5 (2008)
2009  
134
Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.
[19892679] Chest 136(5): 1397-405 (2009)
2008  
135
Radiographic evaluation of arthritis: inflammatory conditions.
[18641245] Radiology 248(2): 378-89 (2008)
2010  
136
New therapeutic approaches for the treatment of rheumatoid arthritis may rise from the cholinergic anti-inflammatory pathway and antinociceptive pathway.
[21103793] ScientificWorldJournal 10(-): 2248-53 (2010)
2011  
137
2010  
138
Rare causes of calcitriol-mediated hypercalcemia: a case report and literature review.
[20427501] J Clin Endocrinol Metab 95(7): 3111-7 (2010)
2011  
139
Possible involvement of glutamatergic signaling machineries in pathophysiology of rheumatoid arthritis.
[21666346] J Pharmacol Sci 116(3): 248-56 (2011)
2010  
140
A role for calreticulin in the pathogenesis of rheumatoid arthritis.
[20958321] Ann N Y Acad Sci 1209(-): 91-8 (2010)
2007  
141
Classification criteria for rheumatoid arthritis--time to abandon rheumatoid factor?
[17215261] Rheumatology (Oxford) 46(5): 725-6 (2007)
2007  
142
Dose escalation of the anti-TNF-alpha agents in patients with rheumatoid arthritis. A systematic review.
[17012439] Rheumatology (Oxford) 46(3): 529-32 (2007)
2005  
143
Leflunomide in rheumatoid arthritis: recommendations through a process of consensus.
[15657072] Rheumatology (Oxford) 44(3): 280-6 (2005)
2008  
144
Interleukin-7 in rheumatoid arthritis.
[18356170] Rheumatology (Oxford) 47(6): 753-9 (2008)
2008  
145
Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis.
[18094000] Rheumatology (Oxford) 47(4): 392-8 (2008)
2008  
146
Hypertension in rheumatoid arthritis.
[18467370] Rheumatology (Oxford) 47(9): 1286-98 (2008)
2008  
147
Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future.
[18503092] Rheumatology (Oxford) 47(10): 1461-8 (2008)
2008  
148
Fractalkine in rheumatoid arthritis: a review to date.
[18495821] Rheumatology (Oxford) 47(10): 1446-51 (2008)
2008  
149
Assessment of anti-TNF-alpha efficacy in rheumatoid arthritis: is 3 months sufficient?
[18503089] Rheumatology (Oxford) 47(7): 1073-6 (2008)
2005  
150
Serum vascular markers and vascular imaging in assessment of rheumatoid arthritis disease activity and response to therapy.
[15644394] Rheumatology (Oxford) 44(6): 721-8 (2005)
2005  
151
Hand surgery in rheumatoid arthritis: state of the art and suggestions for research.
[15797979] Rheumatology (Oxford) 44(7): 834-45 (2005)
2011  
152
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
[21439251] Health Technol Assess 15(14): 1-278 (2011)
2010  
153
Certolizumab pegol (CIMZIA®) for the treatment of rheumatoid arthritis.
[21047485] Health Technol Assess 14(Suppl. 2): 1-10 (2010)
2009  
154
Rituximab for the treatment of rheumatoid arthritis.
[19804686] Health Technol Assess 13 Suppl 2(-): 23-9 (2009)
2006  
155
Methotrexate in rheumatoid arthritis.
[16963793] Pharmacol Rep 58(4): 473-92 (2006)
2010  
156
Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis.
[20193003] Immunol Rev 233(1): 233-55 (2010)
2010  
157
The role of T helper type 17 cells in inflammatory arthritis.
[19758374] Clin Exp Immunol 159(3): 225-37 (2010)
2006  
158
Can we rely on anti-citrulline antibody determination for the diagnosis of early rheumatoid arthritis?
[17143974] J Rheumatol 33(12): 2369-71 (2006)
2010  
159
Matching therapy to body rhythms: an endocrine approach to treating rheumatoid arthritis.
[20889607] J Rheumatol 37(10): 1981-2 (2010)
2005  
160
Discovering that B cells are important in rheumatoid arthritis.
[16265678] J Rheumatol 32(11): 2067-9 (2005)
2004  
161
Estrogen metabolites: increasing evidence for their role in rheumatoid arthritis and systemic lupus erythematosus.
[14994382] J Rheumatol 31(3): 419-21 (2004)
2004  
162
The joy of citrulline: new insights into the diagnosis, pathogenesis, and treatment of rheumatoid arthritis.
[15290721] J Rheumatol 31(8): 1471-3 (2004)
2004  
163
Mechanisms of erosion in rheumatoid arthritis.
[15229936] J Rheumatol 31(7): 1229-37 (2004)
2005  
164
Factors influencing response to disease modifying antirheumatic drugs in patients with rheumatoid arthritis.
[15700388] J Rheumatol 32(1): 11-16 (2005)
2007  
165
All patients with rheumatoid arthritis should receive corticosteroids as part of their management.
[17407224] J Rheumatol 34(4): 656-60 (2007)
2007  
166
N-of-1 trial of low-dose methotrexate and/or prednisolone in lieu of anti-CCP, MRI, or ultrasound, as first option in suspected rheumatoid arthritis?
[17304647] J Rheumatol 34(2): 250-2 (2007)
2008  
167
What can we learn from treatment-induced changes in rheumatoid factor and anti-citrullinated Peptide antibodies?
[18843754] J Rheumatol 35(10): 1903-5 (2008)
2008  
168
Collagen of articular cartilage: the neglected autoantigen of rheumatoid arthritis.
[18464313] J Rheumatol 35(5): 731-3 (2008)
2011  
169
Restoring the balance of the autonomic nervous system as an innovative approach to the treatment of rheumatoid arthritis.
[21607292] Mol Med 17(9-10): 937-48 (2011)
2011  
170
HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis.
[21308151] Mol Med 17(5-6): 397-403 (2011)
2010  
171
Optimal treatment of rheumatoid arthritis: EULAR recommendations for clinical practice.
[20864908] Pol Arch Med Wewn 120(9): 347-53 (2010)
2012  
172
Molecular Mechanisms Governing IL-24 Gene Expression.
[22536164] Immune Netw 12(1): 1-7 (2012)
2011  
173
Stat6 and c-Jun mediate Th2 cell-specific IL-24 gene expression.
[21357535] J Immunol 186(7): 4098-109 (2011)
2010  
174
Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy.
[21116333] Drug Des Devel Ther 4(-): 263-78 (2010)
2003  
175
Newer approaches to the treatment of rheumatoid arthritis.
[14711022] WMJ 102(7): 34-7 (2003)
2010  
176
Remission in rheumatoid arthritis.
[20697983] Curr Rheumatol Rep 12(5): 355-62 (2010)
2009  
177
The role of interleukin-17 in the pathogenesis of rheumatoid arthritis.
[19772832] Curr Rheumatol Rep 11(5): 365-70 (2009)
2009  
178
The role of toll-like receptors in rheumatoid arthritis.
[19772831] Curr Rheumatol Rep 11(5): 357-64 (2009)
2010  
179
Molecular imaging of rheumatoid arthritis by radiolabelled monoclonal antibodies: new imaging strategies to guide molecular therapies.
[19777175] Eur J Nucl Med Mol Imaging 37(2): 386-98 (2010)
2010  
180
Immune aging and rheumatoid arthritis.
[20510235] Rheum Dis Clin North Am 36(2): 297-310 (2010)
2010  
181
Cell-cell interactions in rheumatoid arthritis synovium.
[20510236] Rheum Dis Clin North Am 36(2): 311-23 (2010)
2010  
182
Bone damage in rheumatoid arthritis: mechanistic insights and approaches to prevention.
[20510240] Rheum Dis Clin North Am 36(2): 385-404 (2010)
2010  
183
Cardiovascular complications of rheumatoid arthritis: assessment, prevention, and treatment.
[20510241] Rheum Dis Clin North Am 36(2): 405-26 (2010)
2010  
184
Preclinical rheumatoid arthritis: identification, evaluation, and future directions for investigation.
[20510231] Rheum Dis Clin North Am 36(2): 213-41 (2010)
2010  
185
Leveraging human genetics to develop future therapeutic strategies in rheumatoid arthritis.
[20510233] Rheum Dis Clin North Am 36(2): 259-70 (2010)
2010  
186
Innate immunity and rheumatoid arthritis.
[20510234] Rheum Dis Clin North Am 36(2): 271-96 (2010)
2010  
187
B cells in the pathogenesis and treatment of rheumatoid arthritis.
[20090526] Curr Opin Rheumatol 22(3): 307-15 (2010)
2010  
188
Safety of rituximab in rheumatoid arthritis.
[20657886] Reumatismo 62(2): 101-6 (2010)
2009  
189
Switching between TNFalpha antagonists in rheumatoid arthritis: personal experience and review of the literature.
[19633797] Reumatismo 61(2): 107-17 (2009)
2011  
190
Revolutionary change in rheumatoid arthritis management with biological therapy.
[21979826] Keio J Med 60(3): 75-81 (2011)
2009  
191
Current concepts in the pathogenesis of early rheumatoid arthritis.
[19233044] Best Pract Res Clin Rheumatol 23(1): 37-48 (2009)
2005  
192
Management of the foot in rheumatoid arthritis.
[16129737] J Bone Joint Surg Br 87(9): 1171-7 (2005)
2010  
193
2010 ACR-EULAR classification criteria for rheumatoid arthritis.
[21125184] Rev Bras Reumatol 50(5): 481-3 (2010)
2009  
194
Dendritic cells as targets for therapy in rheumatoid arthritis.
[19798032] Nat Rev Rheumatol 5(10): 566-71 (2009)
2009  
195
Promising bone-related therapeutic targets for rheumatoid arthritis.
[19798028] Nat Rev Rheumatol 5(10): 543-8 (2009)
2009  
196
Japan College of Rheumatology 2009 guidelines for the use of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, in rheumatoid arthritis.
[19590933] Mod Rheumatol 19(4): 351-7 (2009)
2002  
197
Mast cells as a target of rheumatoid arthritis treatment.
[12396022] Jpn J Pharmacol 90(1): 7-11 (2002)
2008  
198
Anti-CCP2 antibodies: an overview and perspective of the diagnostic abilities of this serological marker for early rheumatoid arthritis.
[18270856] Clin Rev Allergy Immunol 34(1): 36-9 (2008)
2010  
199
Adherence to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a narrative review of the literature.
[20664466] Orthop Nurs 29(4): 260-75 (2010)
2009  
200
Chemokines and angiogenesis in rheumatoid arthritis.
[19482623] Front Biosci (Elite Ed) 1(-): 44-51 (2009)
2011  
201
Advances in the medical treatment of rheumatoid arthritis.
[21176795] Hand Clin 27(1): 11-20 (2011)
2008  
202
BH3-only proteins in rheumatoid arthritis: potential targets for therapeutic intervention.
[19641502] Oncogene 27 Suppl 1(-): S168-75 (2008)
2010  
203
2009  
204
Breaking old paradigms: Th17 cells in autoimmune arthritis.
[19403336] Clin Immunol 132(3): 295-304 (2009)
2010  
205
Rheumatoid arthritis pharmacogenomics.
[20415547] Pharmacogenomics 11(5): 617-9 (2010)
2009  
206
Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs.
[19851470] Biologics 3(-): 443-57 (2009)
2009  
207
B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis.
[19707411] Biologics 3(-): 225-32 (2009)
2009  
208
Rheumatoid arthritis: a view of the current genetic landscape.
[18987647] Genes Immun 10(2): 101-11 (2009)
2011  
209
A systematic review of serum biomarkers anti-cyclic citrullinated Peptide and rheumatoid factor as tests for rheumatoid arthritis.
[21915375] Autoimmune Dis 2011(-): 815038 (2011)
2009  
210
Angiogenesis in rheumatoid arthritis.
[19863375] Autoimmunity 42(7): 563-73 (2009)
2010  
211
Tocilizumab: a review of its safety and efficacy in rheumatoid arthritis.
[21234291] Clin Med Insights Arthritis Musculoskelet Disord 3(): 81-9 (2010)
2010  
212
Recent advances in the management of rheumatoid arthritis.
[21177351] BMJ 341(): c6942 (2010)
2010  
213
Rare variation at the TNFAIP3 locus and susceptibility to rheumatoid arthritis.
[20852893] Hum Genet 128(6): 627-33 (2010)
2010  
214
The effectiveness of anti-TNF-alpha therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis.
[20566736] Rheumatology (Oxford) 49(12): 2313-21 (2010)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.


The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia